News

Eli Lilly looks attractively valued, with P/E ratios well below historical averages and robust momentum in Zepbound and ...
On Thursday, Eli Lilly and Co. (NYSE:LLY) said it will sharply increase the list price of its weight-loss and type 2 diabetes ...
Lilly's Kwikpen debut intensifies rivalry with Novo Nordisk's Wegovy in the world's most populous diabetes market ...
Eli Lilly's Mounjaro and Zepbound drove Q2 2025 revenue up 38% and EPS up 92% YoY. Read why LLY stock's recent 20% pullback ...
Eli Lilly stock is down 5% this month despite strong Q2 results and raised guidance, as data from a study on the obesity pill ...
Eli Lilly and Company (NYSE:LLY) is one of the Oversold Fundamentally Strong Stocks to Buy Now. On July 30, the company ...
Eli Lilly and Co (NYSE: LLY) has entered into a $1.3 billion deal with Superluminal Medicines to develop small-molecule drugs ...
Paxton's office said the company supplied free nurses to help care for patients who received its drugs, as well as ...